ATE532065T1 - Antigenziele der autoimmunbedingten schallempfindungsschwerhörigkeit (aisnhl) und entwicklung von tests zur diagnose und behandlung von aisnhl - Google Patents

Antigenziele der autoimmunbedingten schallempfindungsschwerhörigkeit (aisnhl) und entwicklung von tests zur diagnose und behandlung von aisnhl

Info

Publication number
ATE532065T1
ATE532065T1 AT03799763T AT03799763T ATE532065T1 AT E532065 T1 ATE532065 T1 AT E532065T1 AT 03799763 T AT03799763 T AT 03799763T AT 03799763 T AT03799763 T AT 03799763T AT E532065 T1 ATE532065 T1 AT E532065T1
Authority
AT
Austria
Prior art keywords
aisnhl
hearing loss
autoimmune
treatment
sensornetine
Prior art date
Application number
AT03799763T
Other languages
English (en)
Inventor
Thomas Carey
Thankam Nair
Jennifer Beckman
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE532065T1 publication Critical patent/ATE532065T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
AT03799763T 2002-05-06 2003-05-06 Antigenziele der autoimmunbedingten schallempfindungsschwerhörigkeit (aisnhl) und entwicklung von tests zur diagnose und behandlung von aisnhl ATE532065T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/139,496 US20030082646A1 (en) 1998-12-29 2002-05-06 Antigenic targets of autoimmune sensorineural hearing loss (AISNHL) and development of tests for diagnosis and management of AISNHL
PCT/US2003/014248 WO2004041152A2 (en) 2002-05-06 2003-05-06 Antigenic targets of autoimmune sensorineural hearing loss (aisnhl) and development of tests fro diagnosis and management of aisnhl

Publications (1)

Publication Number Publication Date
ATE532065T1 true ATE532065T1 (de) 2011-11-15

Family

ID=32311697

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03799763T ATE532065T1 (de) 2002-05-06 2003-05-06 Antigenziele der autoimmunbedingten schallempfindungsschwerhörigkeit (aisnhl) und entwicklung von tests zur diagnose und behandlung von aisnhl

Country Status (6)

Country Link
US (2) US20030082646A1 (de)
EP (1) EP1508043B1 (de)
AT (1) ATE532065T1 (de)
AU (1) AU2003299473A1 (de)
CA (1) CA2489275C (de)
WO (1) WO2004041152A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082646A1 (en) * 1998-12-29 2003-05-01 The Regents Of The University Of Michigan Antigenic targets of autoimmune sensorineural hearing loss (AISNHL) and development of tests for diagnosis and management of AISNHL
US7829292B2 (en) * 2002-05-06 2010-11-09 The Regents Of The University Of Michigan Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease
DE60335723D1 (de) * 2002-06-27 2011-02-24 Nippon Medical School Foundation Verfahren zum nachweis von perilymphatischen fisteln
CA2605442A1 (en) 2005-04-18 2006-10-26 The Regents Of The University Of Michigan Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease
WO2008070236A2 (en) * 2006-09-07 2008-06-12 The Cleveland Clinic Foundation Diagnostic assay for detecting and monitoring hearing loss
DE102008045696A1 (de) 2008-09-04 2010-03-11 Drk Blutspendedienst West Ggmbh Granulozyten HNA-3a/b-Antigen
JP2022525928A (ja) * 2019-03-21 2022-05-20 ガミダ セル リミテッド 併用療法における移植に適したｎｋ細胞画分の増殖及び増殖ｎｋ細胞画分の使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5422282A (en) * 1991-04-29 1995-06-06 The Regents Of The University Of California Methods for detecting autoimmune sensorineural hearing loss
US20030082646A1 (en) * 1998-12-29 2003-05-01 The Regents Of The University Of Michigan Antigenic targets of autoimmune sensorineural hearing loss (AISNHL) and development of tests for diagnosis and management of AISNHL
US20010006788A1 (en) * 1998-12-29 2001-07-05 Thomas E. Carey Identifying the antigenic target of autoimmune sensorineural hearing loss (aisnhl) and developement of specific tests for diagnosis and management of aisnhl
FR2800750B1 (fr) * 1999-11-05 2003-01-31 Centre Nat Rech Scient Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline
US20030022195A1 (en) * 2001-02-01 2003-01-30 Millennium Pharmaceuticals, Inc. 59914 and 59921, choline transporters and uses therefor

Also Published As

Publication number Publication date
AU2003299473A1 (en) 2004-06-07
WO2004041152A2 (en) 2004-05-21
CA2489275A1 (en) 2004-05-21
EP1508043B1 (de) 2011-11-02
EP1508043A2 (de) 2005-02-23
US20090075268A1 (en) 2009-03-19
WO2004041152A3 (en) 2004-10-14
CA2489275C (en) 2012-12-18
EP1508043A4 (de) 2006-09-06
US20030082646A1 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
Valdor et al. Glioblastoma ablates pericytes antitumor immune function through aberrant up-regulation of chaperone-mediated autophagy
Marsh et al. The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function
Moore et al. Biomaterials direct functional B cell response in a material-specific manner
Lee et al. Gain of HIF-1α under normoxia in cancer mediates immune adaptation through the AKT/ERK and VEGFA axes
Lee et al. Examination of the anaerobic growth of Campylobacter concisus strains
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
WO2006085984A3 (en) Immune cell biosensors and methods of using same
IL129299A0 (en) Monoclonal antibodies antigens and diagnosis of malignant diseases
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
Kakita et al. Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25− FOXP3− T cells
EP1508043A4 (de) Antigenziele der autoimmunbedingten schallempfindungsschwerhörigkeit (aisnhl) und entwicklung von tests zur diagnose und behandlung von aisnhl
MX2009001937A (es) Biomarcadores para el progreso de la enfermedad de alzheimer.
AU3392901A (en) Proteins
DE69935999D1 (de) Methoden zur introduktion heterologer zellen in fische
EP1667716A4 (de) Zytotoxizitätsvermittlung von zellen mit hinweisen auf oberflächenexpression von cd44
DE602006012995D1 (de) Brustkrebsdiagnoseverfahren
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2020023789A3 (en) Small rna predictors for alzheimer's disease
NZ581416A (en) Antibodies useful for therapy and diagnosis of melanoma
SG163614A1 (en) Colon cancer related gene tom34
DE50208908D1 (de) Verfahren zur diagnose von chronisch entzündlichen darmerkrankungen
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
EP1332225A1 (de) Verfahren zur identifizierung abnormaler immunreaktionen
WO2006113723A3 (en) Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease